29.66

0.68% 0.20

Beam Therapeutics Inc (BEAM)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BEAM? Forum Prognose

Schlusskurs vom Vortag:

$29.46

Offen:

$28.91

24-Stunden-Volumen:

1.18M

Relative Volume:

0.55

Marktkapitalisierung:

$3.06B

Einnahmen:

$164.01M

Nettoeinkommen (Verlust:

$-65.04M

KGV:

-43.17

EPS:

-0.687

Netto-Cashflow:

$-383.84M

1W Leistung:

+1.16%

1M Leistung:

+4.62%

6M Leistung:

+8.09%

1J Leistung:

+59.98%

1-Tages-Spanne:

$28.91

$29.97

1-Wochen-Bereich:

$28.02

$30.18

52-Wochen-Spanne:

$18.72

$38.26

Beam Therapeutics Inc Stock (BEAM) Company Profile

Firmenname

Beam Therapeutics Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

857-327-8775

Adresse

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Mitarbeiter

522

Twitter

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BEAM Beam Therapeutics Inc	29.66	2.93B	164.01M	-65.04M	-383.84M	-0.687
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-20	Eingeleitet	Canaccord Genuity	Buy
2025-10-09	Eingeleitet	Jefferies	Buy
2025-03-28	Hochstufung	BofA Securities	Neutral → Buy
2025-03-10	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-07-23	Eingeleitet	H.C. Wainwright	Buy
2024-01-29	Hochstufung	JP Morgan	Neutral → Overweight
2023-12-15	Herabstufung	BofA Securities	Buy → Neutral
2023-12-08	Herabstufung	Jefferies	Buy → Hold
2023-10-20	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Herabstufung	Leerink Partners	Outperform → Market Perform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2023-02-01	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-20	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Eingeleitet	Citigroup	Buy
2022-06-17	Eingeleitet	BMO Capital Markets	Market Perform
2022-04-28	Eingeleitet	Credit Suisse	Neutral
2022-01-05	Eingeleitet	Guggenheim	Buy
2021-10-19	Eingeleitet	SVB Leerink	Outperform
2021-09-24	Fortgesetzt	Stifel	Buy
2021-09-10	Eingeleitet	BofA Securities	Buy
2021-05-11	Eingeleitet	Redburn	Buy
2021-05-04	Eingeleitet	RBC Capital Mkts	Sector Perform
2021-03-01	Herabstufung	Barclays	Overweight → Equal Weight
2021-02-16	Eingeleitet	Wells Fargo	Overweight
2021-01-29	Herabstufung	JP Morgan	Overweight → Neutral
2021-01-06	Eingeleitet	Stifel	Hold
2020-08-05	Eingeleitet	William Blair	Outperform
2020-03-02	Eingeleitet	Barclays	Overweight
2020-03-02	Eingeleitet	JP Morgan	Overweight
2020-03-02	Eingeleitet	Jefferies	Buy
2020-03-02	Eingeleitet	Wedbush	Outperform

Alle ansehen

Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten

Aug 20, 2026

Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2%Here's What Happened - MarketBeat

Aug 20, 2026

Beam (BEAM) Range: Posts a 1.62% Loss to $28.60 on the Day; Current Setup: $27.17 and $30.03 Define the Nearby Reference Levels in the Available RecordDebt Free Companies - Vinanet

Aug 20, 2026

Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters

Aug 20, 2026

Aug 19, 2026

Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current UpdateRevenue Inflection Point - Vinanet

Aug 19, 2026

Beam (BEAM) Today: Adds 6.91% to Close at $28.41 on the Day; Range Check: Price Remains Between $26.99 Support and $29.83 Resistance in the Available RecordRVOL Spike - Vinanet

Aug 19, 2026

Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpShould You Buy? - MarketBeat

Aug 19, 2026

Aug 18, 2026

Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM - MarketBeat

Aug 18, 2026

Aug 17, 2026

Beam Therapeutics (BEAM) Edges Higher as Gene Editing Sector Draws Fresh AttentionCash Secured Put - Vinanet

Aug 17, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 17, 2026

Aug 16, 2026

Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat

Aug 16, 2026

Aug 14, 2026

Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan

Aug 13, 2026

Aug 11, 2026

Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat

Aug 11, 2026